Author

Sara LM Kuusela

University of Helsinki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Antti KukkulaiD· 1 shared Daniel BexelliD· 1 shared Ilkka PaateroiD· 1 shared Lara Kozina Bubnic· 1 shared Maria SundvalliD· 1 shared Saiganesh SriramaniD· 1 shared Verneri VirtaneniD· 1 shared Vilja M. PietiäineniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Antti KukkulaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SUMOylation is a Therapeutic Vulnerability in High-risk Neuroblastoma

Antti Kukkula, Saiganesh Sriraman, Verneri Virtanen, Sara LM Kuusela, Lara Kozina Bubnic, Ilkka Paatero, Vilja M. Pietiäinen, Daniel Bexell, Maria Sundvall

This study identifies SUMOylation as a therapeutic target in high-risk neuroblastoma, showing that SUMO pathway inhibitors like TAK-981 reduce tumor growth and are effective in combination with other therapies.

bioRxiv · Sep 10, 2026 · PreprintCancer Biology